Business Context and Reporting Period
Company: 20/20 Biolabs, Inc. (AIDX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2026
Earliest Event Reported: September 3, 2026
Reporting Period: The filing addresses compliance status as of September 3, 2026, referencing financial data from the Form 10-Q for the period ended June 30, 2026.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. It references specific balance sheet items related to listing compliance:
- Stockholders' Equity: $1,620,700 (as reported in the Form 10-Q for the period ended June 30, 2026).
- Required Stockholders' Equity: $2,500,000 (Nasdaq Listing Rule 5550(b)(1)).
- Stock Price: The closing bid price has been below $1.00 per share for 30 consecutive business days (June 3, 2026, to July 16, 2026).
Material Changes and Compliance Issues
The Company is currently non-compliant with two distinct Nasdaq listing standards:
- Bid Price Rule (Rule 5550(a)(2)):
- Notification received July 17, 2026, for failing to maintain a $1.00 closing bid price.
- Granted a 180-calendar day compliance period ending January 13, 2027.
- Requirement: Maintain a closing bid price of at least $1.00 for 10 consecutive business days within the compliance period.
- Stockholders' Equity Rule (Rule 5550(b)(1)):
- Notification received September 3, 2026, for failing to meet the $2,500,000 equity requirement.
- Current equity of $1,620,700 falls short of the requirement.
- Deadline: 45 calendar days to submit a plan to regain compliance.
Outlook, Risks, and Management Commentary
Management Plan: The Company intends to monitor its stock price and may consider available options to cure deficiencies. It believes its plan to address the equity deficiency will be sufficient, though no assurance is provided that Nasdaq will accept it.
Risks and Contingencies:
- Delisting Risk: Failure to regain compliance with either rule within the allotted periods (including potential extensions) will result in delisting from The Nasdaq Stock Market.
- Interdependency of Rules: If the Company fails to regain compliance with the Equity Rule by January 13, 2027, it will be ineligible for a second 180-day compliance period for the Bid Price Rule.
- Extension Requirements: To qualify for a second compliance period for the Bid Price Rule, the Company must meet all other initial listing standards (excluding the Bid Price Rule) and provide written notice of intent to cure.
Investor Verification Checklist
- Verify the Company's submitted plan to Nasdaq for regaining equity compliance (due within 45 days of September 3, 2026).
- Monitor daily closing bid prices to track progress toward the 10-day $1.00 threshold required for the Bid Price Rule.
- Review upcoming Form 10-Q or 10-K filings to confirm if stockholders' equity has increased to meet the $2.5 million threshold.
- Watch for any Nasdaq hearing panel decisions if the initial equity compliance plan is rejected.
- Confirm whether the Company has announced any capital raise or reverse stock split to address the deficiencies.